Ftse Mib
36.240,82
0,11%
DAX
21.282,18
-0,48%
S&P 500
5.991,62
-1,80%
NASDAQ
19.293,83
-3,31%
Bitcoin
99.723,50
-4,72%
Pepperstone
Advertisement
Registration Strip Icon for discussion Registrati per interagire nei nostri forum attivi per discutere con investitori con idee simili.
Registrati

Quotazioni in diretta

Non abbiamo trovato risultati per:
Assicurati di aver scritto correttamente o prova ad allargare la ricerca.

Più Attivi

Toplist

Sembra che tu non sia connesso.
Clicca il pulsante qui sotto per accedere e visualizzare la tua cronologia recente.

Registrati

Sei già registrato? Accedi

Pepperstone

Inizia Ora

Pepperstone
Home Investire Azioni U.S.A. NASDAQ Chimerix Inc (CMRX) Chimerix Inc (CMRX) Notizie

CMRX

Chimerix (CMRX)

HOME News News di Agenzia

News di Agenzia

Da:
 Ti mostriamo gli articoli più rilevanti per la tua ricerca:NASDAQ:CMRX
DataOraFonteTitoloSimboloCompagnia
24/01/202522:01GlobeNewswire Inc.Chimerix Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)NASDAQ:CMRXChimerix Inc
13/01/202513:00GlobeNewswire Inc.Chimerix to Speak Today at The White House Cancer Moonshot ForumNASDAQ:CMRXChimerix Inc
10/01/202521:01Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:CMRXChimerix Inc
30/12/202413:21Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:CMRXChimerix Inc
30/12/202413:00GlobeNewswire Inc.Chimerix Submits Dordaviprone New Drug Application for Accelerated Approval to U.S. FDA for Patients with Recurrent H3 K27M-Mutant Diffuse GliomaNASDAQ:CMRXChimerix Inc
10/12/202415:55AllPennyStocks.comSmall Cap Soars On FDA Submission PlansNASDAQ:CMRXChimerix Inc
09/12/202422:01GlobeNewswire Inc.Chimerix to Submit Dordaviprone for Accelerated Approval to U.S. FDA for Patients with Recurrent H3 K27M-Mutant Diffuse Glioma Before Year-EndNASDAQ:CMRXChimerix Inc
11/11/202413:00GlobeNewswire Inc.Chimerix Announces Updated Phase 2 Response Assessment of Dordaviprone in Recurrent H3 K27M Glioma at the 2024 SNO MeetingNASDAQ:CMRXChimerix Inc
07/11/202413:28Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:CMRXChimerix Inc
07/11/202413:00GlobeNewswire Inc.Chimerix Reports Third Quarter 2024 Financial Results and Provides Operational UpdateNASDAQ:CMRXChimerix Inc
01/11/202412:00GlobeNewswire Inc.Chimerix to Report Third Quarter 2024 Financial Results and Provide an Operational Update on November 7, 2024NASDAQ:CMRXChimerix Inc
18/10/202422:31GlobeNewswire Inc.Chimerix Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)NASDAQ:CMRXChimerix Inc
03/09/202413:00GlobeNewswire Inc.Chimerix to Present at H.C. Wainwright 26th Annual Global Investment ConferenceNASDAQ:CMRXChimerix Inc
13/08/202422:05Edgar (US Regulatory)Form S-8 - Securities to be offered to employees in employee benefit plansNASDAQ:CMRXChimerix Inc
13/08/202413:00GlobeNewswire Inc.Chimerix Reports Second Quarter 2024 Financial Results and Provides Operational UpdateNASDAQ:CMRXChimerix Inc
09/08/202419:26Edgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNASDAQ:CMRXChimerix Inc
06/08/202413:00GlobeNewswire Inc.Chimerix to Report Second Quarter 2024 Financial Results and Provide an Operational Update on August 13, 2024NASDAQ:CMRXChimerix Inc
30/05/202413:00GlobeNewswire Inc.Chimerix to Participate in Fireside Chat at Jefferies Global Healthcare ConferenceNASDAQ:CMRXChimerix Inc
06/05/202406:15Edgar (US Regulatory)Form EFFECT - Notice of EffectivenessNASDAQ:CMRXChimerix Inc
01/05/202413:00GlobeNewswire Inc.Chimerix Reports First Quarter 2024 Financial Results and Provides Operational UpdateNASDAQ:CMRXChimerix Inc
24/04/202413:00GlobeNewswire Inc.Chimerix to Report First Quarter 2024 Financial Results and Provide an Operational Update on May 1, 2024NASDAQ:CMRXChimerix Inc
21/03/202412:00GlobeNewswire Inc.Chimerix Appoints Marc D. Kozin to Board of DirectorsNASDAQ:CMRXChimerix Inc
29/02/202415:20Edgar (US Regulatory)Form S-3 - Registration statement under Securities Act of 1933NASDAQ:CMRXChimerix Inc
29/02/202414:24Edgar (US Regulatory)Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405]NASDAQ:CMRXChimerix Inc
29/02/202413:00GlobeNewswire Inc.Chimerix Reports Fourth Quarter and Year End 2023 Financial Results and Provides Operational UpdateNASDAQ:CMRXChimerix Inc
27/02/202413:00GlobeNewswire Inc.Chimerix to Present at TD Cowen 44th Annual Health Care ConferenceNASDAQ:CMRXChimerix Inc
22/02/202413:00GlobeNewswire Inc.Chimerix to Report Fourth Quarter and Year End 2023 Financial Results and Provide an Operational Update on February 29, 2024NASDAQ:CMRXChimerix Inc
14/02/202423:01Edgar (US Regulatory)Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]NASDAQ:CMRXChimerix Inc
02/01/202417:07Edgar (US Regulatory)Form 3 - Initial statement of beneficial ownership of securitiesNASDAQ:CMRXChimerix Inc
29/12/202313:00GlobeNewswire Inc.Chimerix Appoints Lisa Decker to Board of DirectorsNASDAQ:CMRXChimerix Inc
 Ti mostriamo gli articoli più rilevanti per la tua ricerca:NASDAQ:CMRX

La tua Cronologia

BIT
BMPS
Banca Monte Dei Paschi D...
BIT
UCG
Unicredit
BIT
PRY
Prysmian
BIT
ISP
Intesa Sanpaolo
BIT
ENEL
Enel
BIT
STMMI
ST Microelectronics
BIT
RACE
Ferrari NV
BIT
STLAM
Stellantis NV
BIT
G
Generali
BIT
MB
Mediobanca Banca di Cred...
BIT
ENI
Eni
BIT
BAMI
Banco BPM
BIT
SRG
Snam
BIT
LDO
Leonardo
BIT
1NVDA
NVIDIA
BIT
SPM
Saipem
Delayed Upgrade Clock
Per accedere al tempo reale push di Borsa è necessario registrarsi.

Il sito ADVFN Italia è stato realizzato ed è gestito da PRODESFIN su licenza di ADVFN PLC.

PER CONTATTI E PUBBLICITA' SUL SITO CLICCARE QUI

Accedendo ai servizi offerti da ADVFN, ne si accettano le condizioni generali Termini & Condizioni

ADVFN Network